• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外用5-氨基酮戊酸光动力疗法治疗光化性角化病。一项剂量范围探索性研究。

Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study.

作者信息

Jeffes E W, McCullough J L, Weinstein G D, Fergin P E, Nelson J S, Shull T F, Simpson K R, Bukaty L M, Hoffman W L, Fong N L

机构信息

Department of Dermatology, University of California, Irvine, USA.

出版信息

Arch Dermatol. 1997 Jun;133(6):727-32.

PMID:9197826
Abstract

OBJECTIVE

To examine the safety and efficacy of photodynamic therapy using topical 5-aminolevulinic acid (ALA) and red light to treat actinic keratoses (AKs).

DESIGN

Actinic keratoses were treated with topical ALA (concentrations of 0%, 10%, 20%, or 30%) under occlusion for 3 hours. Before photodynamic therapy, sites were examined for fluorescence. Sites were irradiated with an argon pumped dye laser (630 nm) at fluences of 10 to 150 J/cm2.

SETTING

Academic medical center.

PATIENTS

Forty patients with 6 clinically typical, previously untreated AKs per patient.

MAIN OUTCOME MEASURE

Complete resolution and decrease in lesion area of the AK relative to baseline evaluated at weeks 1, 4, 8, and 16.

RESULTS

Three hours after ALA administration, lesions showed moderate red fluorescence. Cutaneous phototoxic effects, localized erythema and edema, peaked at 72 hours. Patients experienced mild burning and stinging during light exposure. Eight weeks after a single treatment using 30% ALA, there was total clearing of 91% of lesions on the face and scalp and 45% of lesions, on the trunk and extremities. No significant differences were observed in clinical responses with treatment using 10%, 20%, or 30% ALA. All concentrations of ALA were more effective than treating AKs with vehicle and light.

CONCLUSIONS

Topical photodynamic therapy with ALA is an effective treatment of typical AKs. Complete clearing of nonhypertrophic AKs can be achieved with 10%, 20%, or 30% ALA that is easily tolerated by the patient. Lesions on the face and scalp are more effectively treated than lesions on the trunk and extremities. Hypertrophic AKs did not respond effectively.

摘要

目的

探讨外用5-氨基酮戊酸(ALA)联合红光光动力疗法治疗光化性角化病(AKs)的安全性和有效性。

设计

采用外用ALA(浓度分别为0%、10%、20%或30%)封包3小时治疗光化性角化病。光动力治疗前,检查皮损部位的荧光情况。使用氩离子泵浦染料激光(630nm)以10至150J/cm²的能量密度照射皮损部位。

地点

学术医疗中心。

患者

40例患者,每位患者有6个临床典型、未经治疗的AK皮损。

主要观察指标

在第1、4、8和16周评估AK皮损相对于基线的完全消退情况和皮损面积减小情况。

结果

ALA给药3小时后,皮损呈现中度红色荧光。皮肤光毒性反应,即局部红斑和水肿,在72小时达到峰值。患者在光照期间有轻度灼痛和刺痛感。单次使用30%ALA治疗8周后,面部和头皮上91%的皮损完全清除,躯干和四肢上45%的皮损完全清除。使用10%、20%或30%ALA治疗的临床反应未见显著差异。所有浓度的ALA均比单纯使用赋形剂和光照治疗AK更有效。

结论

外用ALA光动力疗法是治疗典型AK的有效方法。10%、20%或30%的ALA可有效清除非肥厚性AK,患者耐受性良好。面部和头皮上的皮损比躯干和四肢上的皮损治疗效果更好。肥厚性AK治疗效果不佳。

相似文献

1
Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study.外用5-氨基酮戊酸光动力疗法治疗光化性角化病。一项剂量范围探索性研究。
Arch Dermatol. 1997 Jun;133(6):727-32.
2
Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.使用氨基乙酰丙酸对面部和头皮非角化过度性光化性角化病患者进行光动力疗法:一项为期12个月随访的IV期多中心临床试验。
Br J Dermatol. 2006 Dec;155(6):1262-9. doi: 10.1111/j.1365-2133.2006.07520.x.
3
Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light.外用盐酸氨基酮戊酸和荧光蓝光对光化性角化病的光动力治疗
J Am Acad Dermatol. 2001 Jul;45(1):96-104. doi: 10.1067/mjd.2001.114288.
4
Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials.外用氨基酮戊酸溶液联合可见蓝光光动力疗法治疗面部和头皮多发性光化性角化病:研究者设盲的3期多中心试验。
Arch Dermatol. 2004 Jan;140(1):41-6. doi: 10.1001/archderm.140.1.41.
5
Short incubation PDT versus 5-FU in treating actinic keratoses.短疗程光动力疗法与5-氟尿嘧啶治疗光化性角化病的对比
J Drugs Dermatol. 2003 Dec;2(6):629-35.
6
Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study.三种不同光剂量在5-氨基酮戊酸光动力疗法治疗光化性角化病中的疗效:一项随机、观察者盲法、患者自身对照的比较研究。
J Am Acad Dermatol. 2005 Nov;53(5):823-7. doi: 10.1016/j.jaad.2005.06.010.
7
A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage.一项针对面部光化性角化病和弥漫性光损伤的短孵育、大面积光动力疗法试验。
Arch Dermatol. 2004 Jan;140(1):33-40. doi: 10.1001/archderm.140.1.33.
8
Laser-mediated photodynamic therapy of actinic keratoses.光化性角化病的激光介导光动力疗法。
Arch Dermatol. 2003 Oct;139(10):1313-20. doi: 10.1001/archderm.139.10.1313.
9
Topical photodynamic therapy for dermatologic disorders: results and complications.用于皮肤病的局部光动力疗法:结果与并发症
J Drugs Dermatol. 2007 Dec;6(12):1197-202.
10
A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities.一项使用5-氨基酮戊酸和蓝光进行光动力疗法治疗上肢光化性角化病的随机、双盲、双侧个体内、载体对照试验。
J Drugs Dermatol. 2011 Sep;10(9):1049-56.

引用本文的文献

1
Cancer chemoprevention: signaling pathways and strategic approaches.癌症化学预防:信号通路与策略方法
Signal Transduct Target Ther. 2025 Apr 18;10(1):113. doi: 10.1038/s41392-025-02167-1.
2
Clinical development and potential of photothermal and photodynamic therapies for cancer.光热和光动力疗法治疗癌症的临床发展和潜力。
Nat Rev Clin Oncol. 2020 Nov;17(11):657-674. doi: 10.1038/s41571-020-0410-2. Epub 2020 Jul 22.
3
Treatment of actinic cheilitis: a systematic review.光化性唇炎的治疗:系统评价。
Clin Oral Investig. 2019 May;23(5):2041-2053. doi: 10.1007/s00784-019-02895-z. Epub 2019 Apr 23.
4
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.克服ABCG2/BCRP介导的癌症治疗耐药性的新趋势。
J Exp Clin Cancer Res. 2015 Dec 30;34:159. doi: 10.1186/s13046-015-0275-x.
5
In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints.以肿瘤体积和生物标志物表达为终点,对基于电池供电发光二极管的光动力疗法疗效进行体内评估。
J Biomed Opt. 2015 Apr;20(4):048003. doi: 10.1117/1.JBO.20.4.048003.
6
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.咪喹莫特凝胶治疗光化性角化病的成本效用分析:苏格兰视角
Eur J Health Econ. 2016 Apr;17(3):287-304. doi: 10.1007/s10198-015-0679-8. Epub 2015 Mar 21.
7
Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.光化性角化病的综合管理:现有治疗方法的实际整合及一种新治疗方法的综述
J Clin Aesthet Dermatol. 2014 Sep;7(9 Suppl S2-S12):S2-S12.
8
A randomized, double-blind, placebo-controlled clinical trial evaluating Dermytol(®) cream for the treatment of actinic keratoses.一项评估 Dermytol(®)乳膏治疗光化性角化病的随机、双盲、安慰剂对照临床试验。
Clin Cosmet Investig Dermatol. 2014 Aug 7;7:215-24. doi: 10.2147/CCID.S63067. eCollection 2014.
9
Comparative Study of Photodynamic Therapy with Topical Methyl Aminolevulinate versus 5-Aminolevulinic Acid for Facial Actinic Keratosis with Long-Term Follow-Up.外用甲基氨基酮戊酸光动力疗法与5-氨基酮戊酸治疗面部光化性角化病的长期随访对比研究
Ann Dermatol. 2014 Jun;26(3):321-31. doi: 10.5021/ad.2014.26.3.321. Epub 2014 Jun 12.
10
Antibody-based imaging strategies for cancer.基于抗体的癌症成像策略。
Cancer Metastasis Rev. 2014 Sep;33(2-3):809-22. doi: 10.1007/s10555-014-9505-5.